Related Articles
The complementary effect of rs1042522 in TP53 and rs1805007 in MC1R is associated with an elevated risk of cutaneous melanoma in Latvian population
Features associated with melanoma metastasis in Latvia
Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma
Effects of BRAF V600E and NRAS mutational status on the progression‑free survival and clinicopathological characteristics of patients with melanoma
Prognostic value of clinicopathologic variables and DNA ploidy in stage I cutaneous malignant melanoma.